ReviewJournal of functional biomaterials2025
Treatment of Knee Osteoarthritis and Chondral Injury with Umbilical Cord/Wharton's Jelly-Derived Mesenchymal Stem Cells: A Systematic Review of Safety and Efficacy.
Review in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis.Stem cells translational medicine · 2026Pooled it
- Secretome Derived from Umbilical Cord Mesenchymal Stem Cells as a Therapeutic Approach for Osteoarthritis: Insights from In Vitro, In Vivo, and Clinical Evidence.Cell biochemistry and biophysics · 2026Review
- The Influence of Mechanical and Microstructural Characteristics on the Durability of a Femoral Implant Made of Different Alloys.Journal of functional biomaterials · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Stress-Strain State Investigation and Ultimate Load on Femoral Implants Based on S-Type Ti6Al4V Titanium Alloy.Journal of functional biomaterials · 2025Article
- Regenerative Therapy in Osteoarthritis Using Umbilical Cord-Origin Mesenchymal Stem Cells: A Critical Appraisal of Clinical Safety and Efficacy Through Systematic Review and Meta-Analysis.Stem cells international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knee osteoarthritis (KOA) is a major cause of pain and disability worldwide, with no current treatment modality able to prevent the progressive destruction of articular cartilage. Mesenchymal stem cells (MSCs) have attracted interest in treating KOA and cartilage injury due to their self-renewal and multidirectional differentiation potential, as well as local bioactive factors with immunomodulatory and regenerative potential. This study aimed to evaluate the currently available studies using the intra-articular injection of Wharton's jelly MSCs for KOA and cartilage injury. We analyzed all clinical trials published from inception to 31 December 2023. Six studies met the inclusion criteria, for a total of 97 patients and 134 knees. The follow-up period ranged from 3 to 48 months. There were no serious adverse effects noted. There was significant improvement in functional outcomes in the form of VAS, WOMAC, KOOS, and IKDC parameters, though radiological outcomes demonstrated mixed results. In conclusion, patients with KOA treated with intra-articular injections of Wharton's jelly MSCs showed improvements in functional outcomes with no severe adverse effects. Multiple injections of Wharton's jelly MSCs showed better outcomes compared to single-injection techniques. Wharton's jelly MSCs may have potential as a cornerstone in the future treatment of KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.